AbbVie Loses Key Humira Patent In Battle With Small
Coherus Biosciences stock rocketed to a month high wednesday after a U.S. BOARD tossed out a key patent protecting AbbVie's most important drug, arthritis medication Humira, thus clearing an obstacle from a similar treatment from coherus. recently U.S. PTAB, ruled against AbbViein a patent review and invalidated the dosing patent for Humira in rheumatoid [...]





